Gilead Sciences Inc. says that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company's manufacturing facilities.
Apr 29, 2013
0
0
Researchers at the Harvard Stem Cell Institute (HSCI) have discovered a hormone that holds promise for a dramatically more effective treatment of type 2 diabetes, a metabolic illness afflicting an estimated 26 million Americans. ...
Apr 25, 2013
0
0
U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.
Apr 16, 2013
1
0
Mining the records of routine interactions between patients and their care providers can detect drug side effects a couple of years before an official alert from the U.S. Food and Drug Administration, a Stanford University ...
Apr 10, 2013
0
0
(Medical Xpress)—Companies may be misusing the drug patenting system in order to gain control over high-cost drugs in Australia, research from the Melbourne Law School has found.
Apr 10, 2013
0
0
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued ...
Apr 1, 2013
0
0
In a London ceremony today, Wyss Founding Director Don Ingber, M.D., Ph.D., received the NC3Rs 3Rs Prize from the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) for his innovative ...
Feb 26, 2013
0
0
Vitamin D supplement potency varies widely, and the amount of vitamin D in over-the counter and compounded supplements does not necessarily match the amount listed on the label, according to a research letter published in ...
Feb 11, 2013
1
0
Shares of Novo Nordisk tumbled Monday after the Danish drugmaker said U.S. regulators need a new study before they can finish their review of two diabetes treatments, a development that could delay approval for several years.
Feb 11, 2013
0
0
(Medical Xpress)—Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not ...
Feb 8, 2013
0
0
